These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 24928409)

  • 21. Prognostic importance of distressed (Type D) personality and shocks in patients with an implantable cardioverter defibrillator.
    Denollet J; Tekle FB; Pedersen SS; van der Voort PH; Alings M; van den Broek KC
    Int J Cardiol; 2013 Sep; 167(6):2705-9. PubMed ID: 22809538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillator.
    Rho RW; Patton KK; Poole JE; Cleland JG; Shadman R; Anand I; Maggioni AP; Carson PE; Swedberg K; Levy WC
    Circulation; 2012 Nov; 126(20):2402-7. PubMed ID: 23072904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of atrial arrhythmias in a primary prevention ICD population.
    van Gelder IC; Phan HM; Wilkoff BL; Brown ML; Rogers T; Peterson BJ; Birgersdotter-Green UM
    Pacing Clin Electrophysiol; 2011 Sep; 34(9):1070-9. PubMed ID: 21605131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
    Ellenbogen KA; Levine JH; Berger RD; Daubert JP; Winters SL; Greenstein E; Shalaby A; Schaechter A; Subacius H; Kadish A;
    Circulation; 2006 Feb; 113(6):776-82. PubMed ID: 16461817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure treated with combined cardiac resynchronization plus implantable cardioverter-defibrillator therapy versus implantable cardioverter-defibrillator therapy.
    Desai H; Aronow WS; Ahn C; Tsai FS; Lai HM; Gandhi K; Amin H; Frishman WH; Kalapatapu K; Cohen M; Sorbera C
    J Cardiovasc Pharmacol Ther; 2010 Mar; 15(1):37-40. PubMed ID: 19966176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiac perforation from implantable cardioverter-defibrillator lead placement: insights from the national cardiovascular data registry.
    Hsu JC; Varosy PD; Bao H; Dewland TA; Curtis JP; Marcus GM
    Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):582-90. PubMed ID: 24002030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.
    Lin G; Nishimura RA; Gersh BJ; Phil D; Ommen SR; Ackerman MJ; Brady PA
    Heart; 2009 May; 95(9):709-14. PubMed ID: 19282314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure.
    Singh SN; Poole J; Anderson J; Hellkamp AS; Karasik P; Mark DB; Lee KL; Bardy GH;
    Am Heart J; 2006 Nov; 152(5):974.e7-11. PubMed ID: 17070171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mortality and appropriate and inappropriate therapy in patients with ischaemic heart disease and implanted cardioverter-defibrillators for primary prevention: data from the Danish ICD Register.
    Weeke P; Johansen JB; Jørgensen OD; Nielsen JC; Møller M; Videbæk R; Højgaard MV; Riahi S; Jacobsen PK
    Europace; 2013 Aug; 15(8):1150-7. PubMed ID: 23407630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognostic impact of pre-implantation hyponatremia on morbidity and mortality among patients with left ventricular dysfunction and implantable cardioverter-defibrillators.
    Bhavnani SP; Kumar A; Coleman CI; Guertin D; Yarlagadda RK; Clyne CA; Kluger J
    Europace; 2014 Jan; 16(1):47-54. PubMed ID: 23954920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The gender-paradox among patients with implantable cardioverter-defibrillators: a propensity-matched study.
    Bhavnani SP; Pavuluri V; Coleman CI; Guertin D; Yarlagadda RK; Clyne CA; Kluger J
    Pacing Clin Electrophysiol; 2013 Jul; 36(7):878-84. PubMed ID: 23614760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic polymorphisms of the adrenergic system and implantable cardioverter-defibrillator therapies in patients with heart failure.
    Chemello D; Rohde LE; Santos KG; Silvello D; Goldraich L; Pimentel M; Rosa PR; Zimerman L; Clausell N
    Europace; 2010 May; 12(5):686-91. PubMed ID: 20185488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implantable cardioverter-defibrillator therapy before death: high risk for painful shocks at end of life.
    Kinch Westerdahl A; Sjöblom J; Mattiasson AC; Rosenqvist M; Frykman V
    Circulation; 2014 Jan; 129(4):422-9. PubMed ID: 24243857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation.
    Fröhlich GM; Holzmeister J; Hübler M; Hübler S; Wolfrum M; Enseleit F; Seifert B; Hürlimann D; Lehmkuhl HB; Noll G; Steffel J; Falk V; Lüscher TF; Hetzer R; Ruschitzka F
    Heart; 2013 Aug; 99(16):1158-65. PubMed ID: 23813845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential role of home monitoring to reduce inappropriate shocks in implantable cardioverter-defibrillator patients due to lead failure.
    Spencker S; Coban N; Koch L; Schirdewan A; Müller D
    Europace; 2009 Apr; 11(4):483-8. PubMed ID: 19103654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study.
    O'Connor CM; Fiuzat M; Lombardi C; Fujita K; Jia G; Davison BA; Cleland J; Bloomfield D; Dittrich HC; Delucca P; Givertz MM; Mansoor G; Ponikowski P; Teerlink JR; Voors AA; Massie BM; Cotter G; Metra M
    Circ Heart Fail; 2011 Nov; 4(6):724-32. PubMed ID: 21900185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease.
    Omland T; Pfeffer MA; Solomon SD; de Lemos JA; Røsjø H; Šaltytė Benth J; Maggioni A; Domanski MJ; Rouleau JL; Sabatine MS; Braunwald E;
    J Am Coll Cardiol; 2013 Mar; 61(12):1240-9. PubMed ID: 23414791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Troponin T elevation after implanted defibrillator discharge predicts survival.
    Blendea D; Blendea M; Banker J; McPherson CA
    Heart; 2009 Jul; 95(14):1153-8. PubMed ID: 19366711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of cardiac resynchronization therapy on hospitalizations in the Resynchronization-Defibrillation for Ambulatory Heart Failure trial.
    Gillis AM; Kerr CR; Philippon F; Newton G; Talajic M; Froeschl M; Froeschl S; Swiggum E; Yetisir E; Wells GA; Tang AS
    Circulation; 2014 May; 129(20):2021-30. PubMed ID: 24610807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Troponin elevations only detected with a high-sensitivity assay: clinical correlations and prognostic significance.
    Korley FK; Schulman SP; Sokoll LJ; DeFilippis AP; Stolbach AI; Bayram JD; Saheed MO; Omron R; Fernandez C; Lwin A; Cai SS; Post WS; Jaffe AS
    Acad Emerg Med; 2014 Jul; 21(7):727-35. PubMed ID: 25112512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.